FIELD: medicine.
SUBSTANCE: group of inventions relates to the treatment of a bone fracture or bone defect. The use of a gremlin-1 activity inhibitor for the production of a drug for the treatment of a bone fracture or bone defect and a method for the treatment of a bone fracture or bone defect, including the introduction of a therapeutically effective amount of a gremlin-1 activity inhibitor, are proposed. The inhibitor is an anti-gremlin 1 antibody or its functionally active fragment. The antibody contains the sequence SEQ ID NO: 3 or 4 for HCDR1, the sequence SEQ ID NO: 5 for HCDR2, the sequence SEQ ID NO: 6 for HCDR3, the sequence SEQ ID NO: 7 for LCDR1, the sequence SEQ ID NO: 8 for LCDR2 and the sequence SEQ ID NO: 9 for LCDR3.
EFFECT: inventions accelerate the healing and fusion of bone tissue with segmental gap defects, and can provide improved therapy for the treatment or prevention of non-fusion of a fracture.
16 cl, 8 dwg, 6 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CRYSTAL STRUCTURE OF GREMLIN-1 AND INHIBITORY ANTIBODY | 2017 |
|
RU2769285C2 |
| ANTIBODIES TARGETING BONE | 2018 |
|
RU2801206C2 |
| METHOD FOR PREVENTION AND TREATMENT OF CANCER METASTASES AND BONE LOSS CAUSED BY CANCER METASTASES | 2007 |
|
RU2470665C2 |
| USE OF ANTIBODIES TO SCLEROSTIN FOR TREATING OSTEOGENESIS IMPERFECTA | 2017 |
|
RU2789033C2 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
| ANTIBODY SPECIFICALLY BINDING TO N-TERMINAL REGION OF LYSYL-TRNA-SYNTHETASE EXPOSED ON CELL MEMBRANE | 2018 |
|
RU2739393C1 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
